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ARTICLE
Comprehensive Association Testing of Common Mitochondrial
DNA Variation in Metabolic Disease
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Daniel Gaudet, Bo Isomaa, Mark J. Daly, Leif Groop, Kristin G. Ardlie, and David Altshuler
Many lines of evidence implicate mitochondria in phenotypic variation: (a) rare mutations in mitochondrial proteins
cause metabolic, neurological, and muscular disorders; (b) alterations in oxidative phosphorylation are characteristic of
type 2 diabetes, Parkinson disease, Huntington disease, and other diseases; and (c) common missense variants in the
mitochondrial genome (mtDNA) have been implicated as having been subject to natural selection for adaptation to cold
climates and contributing to “energy deficiency” diseases today. To test the hypothesis that common mtDNA variation
influences human physiology and disease, we identified all 144 variants with frequency 11% in Europeans from 1900
publicly available European mtDNA sequences and selected 64 tagging single-nucleotide polymorphisms that efficiently
capture all common variation (except the hypervariable D-loop). Next, we evaluated the complete set of common mtDNA
variants for association with type 2 diabetes in a sample of 3,304 diabetics and 3,304 matched nondiabetic individuals.
Association of mtDNA variants with other metabolic traits (body mass index, measures of insulin secretion and action,
blood pressure, and cholesterol) was also tested in subsets of this sample. We did not find a significant association of
common mtDNA variants with these metabolic phenotypes. Moreover, we failed to identify any physiological effect of
alleles that were previously proposed to have been adaptive for energy metabolism in human evolution. More generally,
this comprehensive association-testing framework can readily be applied to other diseases for which mitochondrial
dysfunction has been implicated.
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Mitochondria play a central role in energy metabolism,
are composed of 1700 known proteins,1 and are essential
for generating ATP and for regulating apoptosis.2 The hu-
man mitochondrial oxidative phosphorylation (OXPHOS)
machinery, which synthesizes most intracellular ATP, con-
sists of five complexes with 85 known protein subunits.
Thirteen OXPHOS subunits, 2 rRNA genes, and 22 tRNA
genes are encoded by the 16.6-kb mitochondrial genome
(mtDNA).
Rare mutations in both nuclear-encoded OXPHOS genes
and in mtDNA result in disease syndromes with neuro-
logical, muscular, or metabolic manifestations, proving
that defects in mitochondrial OXPHOS can play a causal
role in human disease. Mutations in nuclear-encoded
components of OXPHOS complexes have been identified
in many early-onset diseases, such as Leigh syndrome
(MIM 256000) and cardioencephalomyopathy (MIM
604377).2,3 Nuclear genes that encode OXPHOS assembly
factors, influence mtDNA maintenance or translation,
modify mitochondrial tRNA, or encode biosynthetic en-
zymes may be mutated in rare mitochondrial diseases.4,5
In addition, 1250 mtDNA point mutations and deletions
have been linked to human disease, and several of these
include glucose defects or diabetes mellitus as component
phenotypes—for example, mitochondrial myopathy, en-
cephalopathy, lactic acidosis, and stroke-like episodes
(MELAS [MIM 540000]), Kearns-Sayre syndrome (KSS
[MIM 530000]), and maternally inherited diabetes and
deafness syndrome (MIDD [MIM 520000]).6,7 A mutation
in the mitochondrial Leu tRNA gene (A3243G) causes
MIDD,8 and a novel substitution in a highly conserved
region of the mitochondrial Ile tRNA gene (T4291C) causes
hypertension, hypercholesterolemia, and hypomagne-
semia (MIM 500005),9 suggesting that mutations in
mtDNA can cause diabetes and other metabolic defects.
Alterations in the function of OXPHOS have been rec-
ognized consistently in type 2 diabetes (MIM 125853).
Reduced activity of OXPHOS enzymes and fewer, smaller
mitochondria are seen by transmission electron micros-
copy in skeletal muscle from diabetics compared with
nondiabetics.10–12 From global gene-expression–profiling
studies, we and others identified a subset of OXPHOS
genes that are co-coordinately downregulated in muscles
from individuals with type 2 diabetes compared with
healthy control individuals.13,14 In addition, functional in
vivo spectroscopy studies demonstrate that OXPHOS ac-
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Table 1. Clinical Characteristics of the Diabetes Case-Control Study Samples and Quantitative Metabolic Traits in Subjects
Used to Study Genotype-Phenotype Correlations
Sample or Traita n
No. of Males;
Females
Age
(years) BMI
Fasting
Plasma
Glucose
(mmol/liter)
HbA1cb
(%)
Plasma
Glucose
by 2-h OGTT
(mmol/liter) Trait Value
Case-control sample:
Scandinavian:
DM/severe IGT 459 247; 212 60.9  10.2 28.2  4.6 9.8  3.4 … 15.0  5.3 …
NGT 459 247; 212 59.6  10.4 26.3  3.6 6.2  1.8 … 6.8  2.8 …
Swedish:
DM/severe IGT 505 264; 241 66.3  11.8 27.6  4.1 9.8  3.4 6.5  1.5 … …
NGT 505 264; 241 66.6  11.6 27.7  4.1 6.2  1.8 ND ND …
Canadian:
DM 123 67; 56 53.5  7.9 29.2  4.4 6.4  1.8 … 12.8  2.1 …
NGT 123 67; 56 52.1  7.9 28.6  4.1 5.1  0.6 … 6.1  1.1 …
U.S.c:
DM 1,214 641; 573 62.6  11.0 33.0  6.9 9.8  3.0 8.0  3.1 … …
NGT 1,214 641; 573 60.9  9.7 27.4  5.2 5.1  0.9 ND ND …
Polishc:
DM 1,003 420; 583 61.8  9.6 29.6  4.8 8.9  4.0 7.9  1.3 … …
NGT 1,003 420; 583 58.7  7.2 26.1  3.6 4.8  1.2 ND ND …
Trait:
Ins index 342 181; 161 58.5  10.1 26.2  3.6 … … … 22.6  31.3
HOMA-IR 399 210; 189 59.2  10.3 26.3  3.7 … … … 2.1  1.3
Cholesterol 1,274 682; 592 62.5  11.1 27.4  4.2 … … … 6.0  1.2 mmol
Systolic BP 2,047 1,090; 957 62.2  11.7 27.7  4.2 … … … 144  22 mm Hg
Diastolic BP 2,047 1,090; 957 62.2  11.7 27.7  4.2 … … … 83  10 mm Hg
NOTE.—Data are means  SD. ND p not determined.
a BPp blood pressure; DMp diabetes mellitus, type 2; IGTp impaired glucose tolerance; Insp insulinogenic; NGTp normal glucose tolerance.
b HbA1c p hemoglobin A1c.
c Sample from Genomics Collaborative Inc.
Table 2. Common European mtDNA Variants with
Frequency 11%, by Gene of Origin
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
tivity and rates of ATP synthesis are lower in the insulin-
resistant offspring of diabetic individuals and in elderly
insulin-resistant people.15–17
Population genetics analysis has suggested a functional
role for common variants in mtDNA. On the basis of dif-
ferential conservation of missense variants in different
mtDNA lineages, it was argued that positive selection in-
fluenced common mtDNA variation. Moreover, it was
hypothesized that mtDNA SNPs favorable for selective
adaptation to cold Northern climates during human
evolution predispose to energy metabolism diseases
today.2,18,19
These many lines of evidence suggest a “mitochondrial”
hypothesis of disease. Specifically, inherited defects in mi-
tochondria may play a causal role in type 2 diabetes20,21
and neurodegenerative diseases, such as Alzheimer (MIM
104300), Parkinson (MIM 168600), and Huntington (MIM
143100) diseases.22,23 Population genetics analysis specif-
ically suggests that common mtDNA variants may be
functional and relevant to disease. However, no compre-
hensive test, even of common variation in mtDNA, has
yet been performed. Several previous reports did not con-
sistently reproduce associations of common mtDNA var-
iants with diabetes or metabolic traits.24–29 However, these
studies tested only a subset of mtDNA variation in rela-
tively modestly sized samples of !2,000 individuals.
The goal of the present study was to perform a com-
prehensive test of the hypothesis that mtDNA variants
influence type 2 diabetes and metabolic traits. Specifically,
we sought to (1) inventory all SNPs with frequency 11%
in Europeans, (2) select tagging SNPs (tSNPs) to capture
this variation efficiently, (3) test all common variants and
haplogroups for association with type 2 diabetes and a
range of metabolic phenotypes (although sample sizes for
some traits were limited), and (4) assess studywide signif-
icance of our findings by permutation testing.
Material and Methods
Alignment of Sequences
We aligned all human mtDNA coding-region sequences from
GenBank (719 sequences) and 536 sequences from Mitokor30 and
identified 3,240 variant sites. We excluded ∼0.8 kb of the hyper-
variable mtDNA D-loop promoter region from the study, since
this region is best addressed by direct resequencing in case-control
samples because of its high mutation rate.
Subjects and Samples
The sample consisted of 6,608 white subjects from Scandinavia
(Sweden and Botnia, hereafter referred to as the “Swedish” and
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Table 3. Estimated Fraction of mtDNA Coding-Region
Variation Captured by Previous Association Studies
Compared with the Present Study
Study tSNPs Testsa
Percentage of
SNPs Captured
2r  .5 2r  .8
Van der Walt et al.47 9b 9 HGs  9 SNPs 35 30
Huerta et al.49 12b 9 HGs  12 SNPs 33 26
Niemi et al.42 8 9 HGs 34 26
Mohlke et al.27 32c 9 HGs  32 SNPs 54 42
Present study 64 All variants with
frequency 11%
100 100
a HGs p haplogroups.
b One D-loop–region SNP was used to specify haplogroup I; this SNP
was excluded from our evaluation of the coverage of coding-region
mtDNA SNPs.
c Ten SNPs chosen by Mohlke et al.27 (in Finns) were observed at a
frequency !1% in the 928 European sequences of the reference panel.
Table 5. Allele Frequencies of SNPs and
Haplogroups across Five Study Populations
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 4. tSNPs and Tests Used to Predict
All Coding-Region Variants with Frequency
11% in European mtDNA
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1. Procedure for identification and comprehensive dis-
ease-association testing of all common variants in the mtDNA
coding region. 1 and 2, A total of 928 mtDNA sequences of Eu-
ropean origin were aligned to identify 144 variants with frequency
11%. 3, tSNPs and multimarker haplotypes of tSNPs were selected
to capture all 144 variant sites and haplogroups with (a2r  0.8
haplotype of tSNPs [shaded box] captures an untyped SNP [un-
shaded box]). 4, tSNPs were genotyped in a diabetic case-control
panel with available metabolic phenotypes. 5, All hypotheses to
be tested were enumerated. 6, Association tests were performed.
7, Studywide significance of results was assessed by permutation
(multiple rounds of association testing with randomization of case-
control labels or, for quantitative measures, shuffling within a
population).
“Scandinavian” samples, respectively), Canada, Poland, and the
United States; metabolic phenotype information was available for
a subset of the subjects (table 1).31,32 The Scandinavian and Ca-
nadian diabetic case-control samples were matched for sex, age,
region, and BMI (calculated as weight in kilograms divided by
the square of height in meters), whereas the Polish and U.S. case-
control samples were matched for sex, age, and geographical re-
gion but not tightly for BMI. BMI, blood pressure, and cholesterol
values were available for diabetic and nondiabetic subjects from
all five populations, and insulinogenic index and homeostasis
model assessment of insulin resistance (HOMA-IR) values were
obtained for nondiabetic Scandinavian and Swedish subjects
(from a 2-h oral glucose tolerance test [OGTT]). The study of
human subjects was approved by the institutional review boards
at parent institutions for all samples and at the Broad Institute
for Harvard and MIT. Genomic DNA was extracted from blood
samples and lymphoblastoid cell lines.
Genotyping
Genotyping was performed by primer extension of multiplex
products with detection by matrix-assisted laser desorption/ion-
ization time-of-flight mass spectroscopy with use of a Sequenom
platform.33 Genotyping for the 64 tSNPs was 198%; maternal in-
heritance was confirmed for tSNPs by genotyping in 117 CEPH
trios (not shown). Two SNPs (mt14470 and mt15884) were trial-
lelic in this population. Duplicate genotypes were obtained for
∼20% of the sample with 22 SNPs and were highly concordant
(0.1% discordant genotypes of 29,462 duplicate comparisons).For
69 samples (1.1% of samples genotyped), we observed spectral
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Table 6. Results of Association Testing of All mtDNA Variants with Type 2
Diabetes and Metabolic Traits
Phenotypea n Best Result Effect Estimateb (95% CI) Pnom Pempirical
c
DM 6,608 mt12612 (syn ND5) 1.25 (1.05–1.49) .011 1.55 (NS)
BMI 6,523 mt9123 (mis ND3) .04 (.05 to .03) .0027 1.0 (NS)
Ins Index 342 mt3197 (16S rRNA);
mt9477 (mis COIII);
mt13617 (syn ND5)
.14 (.19 to .09) .012 1.3 (NS)
HOMA-IR 399 mt4561 (mis ND2) .102 (.052–.152) .042 1.26 (NS)
Cholesterol 1,274 mt15784 (syn cytB) .10 (.07–.13) .0003 1.08 (NS)
Systolic BP 2,047 mt4561 (mis ND2) .045 (.065 to .025) .042 1.35 (NS)
Diastolic BP 2,047 mt3394 (tRNA S) .022 (.001 to .045) .12 1.5 (NS)
a BP p blood pressure; DM p diabetes mellitus, type 2; Ins p insulinogenic.
b OR for DM and standardized regression coefficient (b) for all other phenotypes (the quantitative
traits).
c NS p not significant.
Table 8. Results of Association Testing
of Each SNP and Haplogroup with Type 2
Diabetes, BMI, and Metabolic Traits
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 7. Association Testing with Type 2
Diabetes, BMI, and Metabolic Traits
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
peaks for both the major and minor allele for 1–3 SNPs per sam-
ple. In total, 21 SNPs had heterozygous calls in at least one in-
dividual. These observations are consistent with either DNA con-
tamination or heteroplasmy (more than one mtDNA haplotype
arising from somatic/maternal germ line mutations or from the
paternal mtDNA contribution). Signals for both alleles were seen
in individuals from all populations, and no significant difference
in the number of cases and controls with such genotypes was
observed. For analysis, these genotypes were treated as missing
data.
Results
Previous studies have tested subsets of mtDNA vari-
ants (from 10–32 sites) for association with a variety of
traits,24–27,34–49 typically focusing on the nine canonical
haplogroups.50 We began by cataloging all common sites
(frequency 11%) in 15,770 bp of mtDNA (excluding the
coding region) and by evaluating how well the complete
inventory is captured by these canonical haplogroups in
mtDNAs of European origin. Alignment of 928 European
coding-region mtDNA sequences (115,770 bp) identified
2,349 variable sites; 144 sites had a frequency 11% in Eu-
ropean individuals (1 site per 110 bp), including 37 non-
synonymous variants, 81 synonymous variants, 25 rRNA/
tRNA variants, and 1 noncoding variant (table 2). Fifty
variants with frequency 15% were identified. The com-
mon variants (frequency 11%) explained 72% of the “het-
erozygosity” in the European population; this is notably
less than in the nuclear genome, where ∼90% of hetero-
zygosity is due to common variants.51–53
Evaluation of previous sets of tSNPs used for disease
association studies revealed that ∼30% of variants (fre-
quency 1%) are captured with (table 3). Re-2r  0.8
cently,27 more-complete coverage of mtDNA variation was
reported using 32 mtDNA SNPs; still, these SNPs capture
less than half of the sites (42%) at . Thus, previous2r  0.8
studies might have missed a true association simply be-
cause not all variants were captured by the tSNPs used.
We selected a set of 64 SNPs that capture each of the
144 sites as well as the nine haplogroups with ,2r  0.8
using Tagger54; tSNPs and predictive tests are listed in table
4. Details on the assay conditions are available online
(Broad Institute Tagger: SNPs in human mtDNA Web site).
As a framework to test common mtDNA variants for
association with clinical traits (fig. 1), we first enumerated
all hypotheses to be tested for association. Specifically, we
sought to test for association with each phenotype for
each of the individual 144 variant sites with frequency
11% as well as for the nine previously codified European
haplogroups. Association tests for type 2 diabetes (the di-
chotomous trait) were performed by x2 comparisons,2# 2
and, for quantitative phenotypes, by linear regression. Stu-
dywide significance (Pstudy) was empirically evaluated by
permutation testing (association studies were repeated 50–
1,000 times by using randomized phenotype labels within
each case-control pair for diabetes and by using random-
ized trait values within each of five populations for quan-
titative traits). We also tested all pairwise combinations of
single variants with a nominal P value (Pnom) !.1 (another
∼600 correlated hypotheses) for association with diabetes
and BMI.55
As a test of the hypothesis that common mtDNA vari-
ation plays a causal role in disease, we considered asso-
ciation with type 2 diabetes and metabolic traits. We ge-
notyped each of the 64 tSNPs in a diabetes case-control
sample of 6,608 subjects, with quantitative measurements
available for a subset of subjects (table 1). Under the as-
sumption of ∼100 independent tests performed in this
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Table 9. Results of Association Testing of All mtDNA Variants with Type 2
Diabetes, by Population
Sample n Best Result OR (95% CI) Pnom Pempirical
a
Scandinavian 918 mt8869 (misATP6);
mt5263 (misND2);
mt4639 (misND2)
7.67 (2.18–27.04) .0015 1.5 (NS)
Swedish 1,010 mt8251 (synCOII) 2.56 (1.25–5.26) .0105 1.5 (NS)
Canadian 246 mt15218 (misCytB) 3.93 (1.16–13.28) .0277 1 (NS)
U.S.b 2,428 mt5495 (synND2) 3.60 (1.42–9.12) .0070 1.3 (NS)
Polandb 2,006 mt12612 (synND5) 2.07 (1.44–2.98) .000085 .02
a NS p not significant.
b Sample from Genomics Collaborative Inc.
Table 10. Results of Association Testing
of Each SNP and Haplogroup with Type 2
Diabetes, by Population
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
study, this sample has 177% power to reject the null hy-
pothesis of no association between mtDNA variants and
type 2 diabetes at for a 5% risk allele with a 1.5P ! .05
genotype relative risk and has 198% power for risk alleles
with frequency 110%.56 Allele frequencies for SNPs dif-
fered across the populations tested (table 5).
Results from association studies with type 2 diabetes and
BMI are shown in tables 6, 7, and 8. For diabetes, only
two hypotheses with were found, and these re-P ! .05nom
sults were far from significant after permutation testing
(50–1,000 iterations for each association test) (P pstudy
). For BMI, we found no significant association before.55
( ) or after ( ) adjustment for sex andP p 1.0 P p .25study study
age. Tests for epistasis did not demonstrate any significant
association with diabetes or BMI. Subanalysis of associa-
tion with diabetes by population failed to show any strong
effects in U.S., Scandinavian, and Canadian populations
(tables 9 and 10). A significant association result was ob-
served in the Polish subpopulation after permutation test-
ing ( after 1,000 permutations); however,P p .02Polish study
given that mtDNA variants from five populations were
tested for association with diabetes, this result is consistent
with noise and thus would need to be validated by rep-
lication in other large Polish samples.
The remaining quantitative metabolic traits were stud-
ied only in nondiabetic controls, and sample sizes for
these additional studies were significantly smaller than for
diabetes or BMI (tables 6, 7, and 8). No significant asso-
ciations were identified using unadjusted models for in-
sulin resistance (HOMA-IR), insulin secretion (insulino-
genic index), cholesterol levels, and systolic and diastolic
blood pressure (table 6) or after adjustment for sex, age,
and BMI (tables 7 and 8).
We specifically examined the results for the three mis-
sense variants that were hypothesized to have been adap-
tive in cold climates and to be related to “energy defi-
ciency” diseases today.18,19 No association with increased
risk of diabetes, obesity, or other metabolic traits was ob-
served (table 11). The putative association of mt16189C
with type 2 diabetes reported elsewhere24–26 was not rep-
licated here ( ; odds ratio [OR] 1.03; 95% CI 0.88–np 6,608
1.21; ), which is consistent with other recentP p .36nom
reports that did not support this hypothesis.27,28 With this
sample size (under the assumption of an OR of 1.5 and
an mt16189C allele frequency of 14%, consistent with pre-
vious reports), we have 199% power to reject the null
hypothesis (of no association) at the level.56P ! .01
Discussion
We set out to develop a comprehensive approach to
mtDNA association testing that (a) captures all common
coding-region mtDNA variants and haplogroups effi-
ciently by use of linkage disequilibrium, (b) tests all com-
mon variants for association, and (c) accounts for the mul-
tiple comparisons implicit in testing the many variants in
mtDNA. Compared with the methods in the literature,
this approach provides a more complete and statistically
conservative assessment of the role of common mtDNA
variants in disease; the current application to diabetes and
BMI provides a sample size threefold larger than any pre-
vious study.
Despite this well-powered evaluation, our analyses do
not support the hypothesis that common mtDNA variants
play a role in type 2 diabetes and BMI, at least in the
European samples studied. The results from our associa-
tion tests of all common mtDNA variants and the risk of
type 2 diabetes show that there is no single common cod-
ing-region mtDNA variant in European populations that
strongly influences risk of type 2 diabetes or BMI, which
is consistent with recent results obtained by Mohlke et
al.27 Haplogroup association results for type 2 diabetes
were also consistent with noise. There may be population-
specific variants that confer altered risk of diabetes (as in
the Polish sample tested here), and further studies, in-
cluding replication and complete resequencing,57 will be
needed to explore that hypothesis. Our results showed no
significant association of mtDNA variants with other met-
abolic traits (blood pressure, cholesterol, insulin secretion,
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Table 11. Results of Association Testing of Three European mtDNA Variants Predicted to
Be Selected for Adaptation to Cold Climates
Phenotypea n
mt4917G
(ND2 N150D)
mt14798C
(cytB F18L)
mt15257A
(cytB D171N)
Effect Estimateb Pnom Effect Estimate
b Pnom Effect Estimate
b Pnom
DM 6,608 .89 (.76–1.05) .16 .93 (.81–1.07) .30 .87 (.61–1.23) .47
BMI 6,523 .002 .56 .002 .59 .006 .39
Ins index 342 .04 .29 .05 .37 .31 .13
HOMA-IR 399 .03 .59 .04 .27 .09 .55
Cholesterol 1,274 .13 .29 .03 .81 .45 .05
Systolic BP 2,047 .49 .76 1.13 .47 .39 .90
Diastolic BP 2,047 .07 .92 .59 .43 1.94 .21
a BP p blood pressure; DM p diabetes mellitus, type 2; Ins p insulinogenic.
b OR (95% CI) for DM and b for all other phenotypes.
and insulin resistance traits); however, this study was not
as well powered for these traits.
It is interesting and perhaps surprising that we could
not detect any phenotypic consequence of missense var-
iants that were predicted to have been selected for in
colder climates.2,19,58 Although our study does not directly
address the hypothesis that climatic influences have led
to selective adaptation of mtDNA variants, if common
mtDNA variation does influence such traits, it is not re-
flected in glucose-stimulated insulin secretion, insulin re-
sistance, body weight, blood pressure, cholesterol level, or
type 2 diabetes.
This study does not address the role of mtDNA hetero-
plasmy in diabetes. Acquired somatic mtDNA mutations
in tissues of relevance to type 2 diabetes are undetected
in the blood samples used here. Typically, blood DNA ex-
hibits much less heteroplasmy than nondividing tissues.59
In the 6,608 DNA samples tested, a very small amount of
heteroplasmy was observed (1.1% of samples had one or
more “heterozygous” calls), although the mass spectros-
copy–based genotyping platform is sensitive to low-fre-
quency spectral peaks corresponding to the alternate
allele. Rare mitochondrial diseases exhibit more pro-
nounced heteroplasmy, perhaps because cells with mutant
alleles are inviable without wild-type mtDNA molecules.
Thus, we think it is unlikely that mtDNA heteroplasmy
for inherited variants significantly influenced our results.
These results should not be taken as addressing the
broader hypothesis that mitochondrial OXPHOS plays a
causal role in type 2 diabetes; there are 170 nuclear-en-
coded OXPHOS subunits and an estimated 1,500 mito-
chondrial proteins that are as yet untested. Moreover, al-
though the mtDNA variants tested here do not appear to
influence metabolic disease, inherited variation in mtDNA
may influence risk of other diseases, such as Alzheimer
disease, Parkinson disease, cardiovascular disease, cardio-
myopathy, HIV lipodystrophy, and prostate cancer. A sys-
tematic evaluation of mtDNA and nuclear mitochondrial
genes for a causal role in these diseases and an investi-
gation of epistatic interactions between the two genomes
will reveal the extent to which mitochondrial defects play
a causal role in human disease.
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